Tegoprubart (antiCD40L) is a monoclonal antibody therapeutic with comprehensive and promising preclinical data. It blocks specific immune cell activation and protects nerves against the progression of ALS and Alzheimer's disease. Tegoprubart successfully completed a Phase 2a clinical trial in May of 2022.

Copper complexes, also known as redox metabolism modulators, are a group of molecules that can more safely deliver copper ions to cells in the body. Several of these molecules have demonstrated evidence of efficacy in both induced pluripotent stem cell (iPSC) and animal models of ALS. ALS TDI scientists are currently working to identify a lead copper complex molecule, which could become the next drug that we advance to human clinical trials.

Type I protein arginine methyltransferases (PRMT) inhibitors are a class of molecules currently being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS) at the ALS Therapy Development Institute (ALS TDI). ALS TDI researchers believe these molecules may affect a process called asymmetric dimethylation, which was discovered as a drug target for C9orf72-related ALS by ALS TDI in 2020.